Investor Presentation Q2FY23

Zifi - Category Leader in CEFIXIME Zifi - Consistent Category Leader (Market Share) 23.9% 24.8% 24.7% MAT Sep 20 MAT Sep 21 MAT Sep 22 Multiple SKUs to Driving Consistent Growth QU 002BIZ CEFIXIME TABLETS IP 200 mg ZIFI 200 ज़िफी २०० FDC Prete Source: IQVIA-Moving Annual Total Turnover- MAT Sep 2022 R CEFIXIME ORAL SUSPENSION IP 50 mg/5 ml ZIFI 50 DRY SYRUP ज़िफी ५० ड्राइ सिरप WITH STERILE WATER FOR RECONSTITUTION 15g Powder furni sponsion 30 ml FDC In an otherwise fragmented market (Market Shares of Other Players) Market Share in MAT Sep 20 Market Share in MAT Sep 22 22.5% 23.1% 5.5% 5.7% 4.9% 5.7% 6.4% 5.5% TAXIM-O CEFOLAC OMNICEF-O MAHACEF 1(c) FDC

View entire presentation